DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
STIs can be a red flag for HIV risk
In a real-world study (n=214), 51% of people newly diagnosed with HIV had an STI history that included chlamydia, gonorrhea, or syphilis1
Behaviors that can result in an STI can also increase the risk of HIV. These may include sex2,3:
A record high of 2.5 million new cases of syphilis, gonorrhea, and chlamydia combined were reported in 20184
- Be the catalyst—start an open conversation with your patients about STIs and HIV risk
High HIV prevalence can mean increased HIV risk5,6
Talk to your appropriate sexually active patients in high-prevalence communities about DESCOVY FOR PrEP®
Patients can be at risk simply by being sexually active in regions, neighborhoods, or even social
networks with higher HIV prevalence.5,7
Lifetime risk of HIV diagnosis by state7,a
Select a filter below to view statistics.
Individuals in all neighborhoods and communities can be at risk for HIV.5
a Risk data from 2016 CDC report.
b Chances of an individual being diagnosed with HIV during their lifetime.
CDC=Centers for Disease Control and Prevention; STI=sexually transmitted infection.